Angiomotin-like protein 2 (AMOTL2)

Angiomotin-like protein 2 (AMOTL2) is a member of the motin family of proteins, which are involved in the regulation of endothelial cell morphology, motility, and proliferation[1][3]. AMOTL2 functions as a scaffold and adaptor protein at cell–cell junctions, especially tight junctions, and is a crucial activator of the Hippo signaling pathway through direct binding and activation of the LATS2 kinase[2][3]. In this role, AMOTL2 promotes phosphorylation and cytoplasmic sequestration of the transcriptional coactivators YAP and TAZ, thereby inhibiting their ability to drive pro-proliferative gene expression. AMOTL2 also participates in actin cytoskeleton organization, maintaining cell architecture and epithelial sheet integrity[3]. It is implicated in processes such as angiogenesis, tissue growth, and cancer progression, largely through its control of Hippo pathway signaling and regulation of contact inhibition[1][2][3]. There are currently no known drugs targeting AMOTL2 directly, and no clinical biomarkers or safety liabilities have been firmly established. **Note:** - "Angiomotin-like protein 2" is the most accurate and common full name, with "AMOTL2" as its canonical abbreviation[1][3]. - It is not a receptor, enzyme, transporter, or typical drug target, but is a key scaffold/adaptor in cell signaling pathways, most notably the Hippo pathway[2][3]. - The main relevance to disease is its role in cancer via modulation of cell proliferation and migration[2][3]. - No well-established AMOTL2-targeted therapeutics or biomarkers currently exist[3].

Other names

Angiomotin-like 2AMOTL2Motin family protein

Functions as a scaffold for Hippo pathway proteins, promoting activation of LATS2 kinase and suppression of YAP/TAZ transcriptional coactivator activity. Inhibits Wnt/β-catenin pathway by sequestering CTNNB1 (β-catenin). Sequesters YAP/TAZ in the cytoplasm at tight junctions to repress their activity.